Telomir Pharmaceuticals, Inc. (TELO): M&A transaction — Telomir Pharmaceuticals completes acquisition of TELI, consolidating global rights to Telomir-1

Telomir Pharmaceuticals, Inc.

Acquired 100% of TELI for 34,389,710 restricted shares of Telomir common stock to former TELI shareholders.
Bayshore Trust contributed $1 million at closing and has an option to provide up to $4 million upon IND acceptance and Phase 1/2 study start.
Option includes $2 million for 1,492,537 shares at $1.34 per share upon FDA IND acceptance, and another $2 million for the same number of shares upon Phase 1/2 initiation.
Transaction eliminates prior geographic fragmentation, giving Telomir full worldwide control of Telomir-1 development and commercialization.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Telomir Pharmaceuticals, Inc. completed an acquisition involving TELI Pharmaceuticals, Inc. for 34,389,710 restricted shares of the Company’s common stock (closed 2026-04-22).

Action: acquisition
Counterparty: TELI Pharmaceuticals, Inc.
Consideration: 34,389,710 restricted shares of the Company’s common stock
Closing: 2026-04-22

Exact text from the filing

by the Company’s shareholders during the Company’s annual shareholders meeting on March 23, 2026. At closing, the Company acquired 100% of TELI in exchange for a total of 34,389,710 restricted shares of the Company’s common stock, no par value issued to TELI’s former shareholders (the “Shares”). The number of shares issued was determined based on an exchange

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Telomir Pharmaceuticals, Inc. entered into Commitment Agreement with Bayshore Trust (effective 2026-04-22).

Action: entry
Agreement: asset purchase
Counterparty: Bayshore Trust
Effective: 2026-04-22

Exact text from the filing

On April 22, 2026, Telomir Pharmaceuticals, Inc. (the “Company”) completed its acquisition of TELI Pharmaceuticals, Inc. (“TELI”) pursuant to the previously announced merger agreement (the “Transaction”).

View on SEC.gov

31 m&a transactions filed in the last 30 days. Browse all m&a transactions →

Telomir Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-018867

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.